No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan

CHIA-HSUIN CHANGYI-CHENG CHANGJOU-WEI LINCaffrey, James LJames LCaffreyWu, Li-ChiuLi-ChiuWuLai, Mei-ShuMei-ShuLaiLEE-MING CHUANG2022-12-302022-12-302016-10-010167-5273https://scholars.lib.ntu.edu.tw/handle/123456789/626872Saxagliptin has been reported to be associated with an increased risk of hospitalization for heart failure (HF). The objective of this study was to test whether the increased risk is drug specific or a class effect for dipeptidyl peptidase-4 (DPP-4) inhibitors.enDipeptidyl-Peptidase 4 Inhibitors; Heart Failure; HospitalizationNo increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwanjournal article10.1016/j.ijcard.2016.06.125273894372-s2.0-84978472596WOS:000381582000003https://api.elsevier.com/content/abstract/scopus_id/84978472596